ScholarIQanswers from OpenAlex & ORCID
Amrita Krishnan
ResearcherPublications, citations & collaboration network
Amrita Krishnan is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Amrita Krishnan have?
ScholarIQindexed works
Amrita Krishnan has 394 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Amrita Krishnan have?
ScholarIQcitation count
Amrita Krishnan has 17,623 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Amrita Krishnan?
ScholarIQh-index
Amrita Krishnan has an h-index of 59 in OpenAlex.
What is the i10-index of Amrita Krishnan?
ScholarIQi10-index
Amrita Krishnan has an i10-index of 168 in OpenAlex.
What is the OpenAlex record for Amrita Krishnan?
ScholarIQopenalex
The OpenAlex for Amrita Krishnan is on the source record.
What are the most-cited papers on Amrita Krishnan?
ScholarIQmost cited works
Teclistamab in Relapsed or Refractory Multiple Myeloma
Philippe Moreau, Alfred L. Garfall, Niels W.C.J. van de Donk, Hareth Nahi, Jesús F. San Miguel, Albert Oriol, Ajay K. Nooka, Thomas G. Martin, Laura Rosiñol, Ajai Chari, Lionel Karlin, Lotfi Benboubker, María‐Victoria Mateos, Nizar J. Bahlis, Rakesh Popat, Britta Besemer, Joaquín Martínez‐López, Surbhi Sidana, Michel Delforge, Lixia Pei, Danielle Trancucci, Raluca Verona, Suzette Girgis, Shun Xin Wang Lin, Yunsi Olyslager, Mindy Jaffe, Clarissa Uhlar, Tara Stephenson, Rian Van Rampelbergh, Arnob Banerjee, Jenna D. Goldberg, Rachel Kobos, Amrita Krishnan, Saad Z. Usmani
Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
Ajai Chari, Monique C. Minnema, Jesús G. Berdeja, Albert Oriol, Niels W.C.J. van de Donk, Paula Rodríguez‐Otero, Elham Askari, María‐Victoria Mateos, Luciano J. Costa, Jo Caers, Raluca Verona, Suzette Girgis, Shiyi Yang, Rachel B. Goldsmith, Xiang Yao, Kodandaram Pillarisetti, Brandi Hilder, Jeffery S. Russell, Jenna D. Goldberg, Amrita Krishnan
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
Saad Z. Usmani, Alfred L. Garfall, Niels W.C.J. van de Donk, Hareth Nahi, Jesús F. San Miguel, Albert Oriol, Laura Rosiñol, Ajai Chari, Manisha Bhutani, Lionel Karlin, Lotfi Benboubker, Lixia Pei, Raluca Verona, Suzette Girgis, Tara Stephenson, Yusri Elsayed, Jeffrey R. Infante, Jenna D. Goldberg, Arnob Banerjee, María‐Victoria Mateos, Amrita Krishnan
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial
Edward A. Stadtmauer, Marcelo C. Pasquini, Beth Blackwell, Parameswaran Hari, Asad Bashey, Steven M. Devine, Yvonne A. Efebera, S. Ganguly, Cristina Gasparetto, Nancy L. Geller, Mary M. Horowitz, John Koreth, Kristin Knust, Heather Landau, Claudio G. Brunstein, Philip L. McCarthy, Courtney Nelson, Muzaffar H. Qazilbash, Nina Shah, David H. Vesole, Ravi Vij, Dan T. Vogl, Sergio Giralt, George Somlo, Amrita Krishnan